ArticleVaccine2010
Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer.PharmacoEconomics · 2016Pooled it
- Safety profile of India's influenza vaccine in a large-scale corporate vaccination drive.Human vaccines & immunotherapeutics · 2026Observational
- Workplace Vaccination Against COVID-19 and Seasonal Influenza in the United States: A Modeling-Based Estimation of the Health and Economic Benefits for Employers and Employees.Journal of market access & health policy · 2025Article
- Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review.Vaccines · 2021Review
- Patient care aides: Differences in healthcare coverage, health-related behaviors, and health outcomes in a low-wage workforce by healthcare setting.American journal of industrial medicine · 2020Article
- Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study.Vaccine · 2017Article
- Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study.American journal of epidemiology · 2017Article
- The potential economic burden of Zika in the continental United States.PLoS neglected tropical diseases · 2017Article
- How to determine if a model is right for neglected tropical disease decision making.PLoS neglected tropical diseases · 2017Article
- A systems approach to vaccine decision making.Vaccine · 2017Article
- A systems approach to obesity.Nutrition reviews · 2017Review
- Is population structure sufficient to generate area-level inequalities in influenza rates? An examination using agent-based models.BMC public health · 2015Article
- Quantifying the economic value and quality of life impact of earlier influenza vaccination.Medical care · 2015Article
- The cost of an Ebola case.Pathogens and global health · 2015Article
- Influenza vaccination coverage among school employees: assessing knowledge, attitudes, and behaviors.The Journal of school health · 2014Article
- Policies to reduce influenza in the workplace: impact assessments using an agent-based model.American journal of public health · 2013Article
- Planning influenza vaccination programs: a cost benefit model.Cost effectiveness and resource allocation : C/E · 2012Article
- Impact of introducing the pneumococcal and rotavirus vaccines into the routine immunization program in Niger.American journal of public health · 2012Article
- Would school closure for the 2009 H1N1 influenza epidemic have been worth the cost?: a computational simulation of Pennsylvania.BMC public health · 2011Article
- The 2009 H1N1 influenza pandemic: a case study of how modeling can assist all stages of vaccine decision-making.Human vaccines · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Employers may be loath to fund vaccination programs without understanding the economic consequences. We developed a decision analytic computational simulation model including dynamic transmission elements that estimated the cost-benefit of employer-sponsored workplace vaccination from the employer's perspective. Implementing such programs was relatively inexpensive (<$35/vaccinated employee) and, in many cases, cost saving across diverse occupational groups in all seasonal influenza scenarios. Such programs were cost-saving for a 20% serologic attack rate pandemic scenario (range: -$15 to -$995) per vaccinated employee) and a 30% serologic attack rate pandemic scenario (range: -$39 to -$1,494 per vaccinated employee) across all age and major occupational groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.